Add your company: HE Business Directory, get listed today.
AGENDA RELEASED! Register today for 1st ever VIRTUAL Summit on Real World Evidence Needs and Practical Success Strategies: A Multi-Stakeholder Perspective
|IN THIS ISSUE|
|Most complete Jobs, Conferences, and Webinars list anywhere. Need to add one? Click Here.|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|Are Specialty Drug Prices Destroying Insurers And Hurting Consumers?|
Organizations are trying to address the high cost of specialty medications that treat conditions such as cancer, hepatitis C, and Multiple Sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending. (Source: Pharmacy & Therapeutics, Vol 39, August 2014).
|Express Scripts Says Bye-Bye To High Cost Products|
Express Scripts Holding Co has recently announced the removal of 25 products from its 2015 list of preferred drugs. The products being removed cost significantly more than other available options but without additional health benefit. Being the largest U.S. pharmacy benefit manager and a vocal critic of rising prescription drug prices, the company has the ability to drive enormous revenue toward drug makers whose products it selects. (Source: Reuters, 8/1/14).
|Take A Look At Oncology Pricing’s Growth Chart|
We all know that cancer drugs are expensive, but this graph may still surprise you as it takes a look at the cost of one month of treatment for an adult for each new cancer drug approved by the United States Food and Drug Administration. (Source: Flag media, 8/2/14).
|Is Hepatitis C Soon To Be A Thing Of The Past?|
With the double-punch combination of screening initiatives and the availability of direct-acting antivirals, such as Sovaldi, Hepatitis C could be on its way out the door. HCV is expected to be a rare disease by 2036, and by the year 2050, some analyses have predicted a virtual elimination of HCV. (Source: Michael Page, Specialty Pharmacy Times, 8/8/14).
|NYTimes on Sticker Shock With Sovaldi – The Mass-Market Specialty Drug|
The new hepatitis C drug, Sovaldi, is not the most expensive drug on the market, so why is it getting so much negative feedback? This article is accompanied by charts explaining why Sovaldi is in a league of its own. (Source: The New York Times, 8/6/14).
|AMCP Nexus 2014 – Who Will You Be Hearing From?|
AMCP 2014 Nexus will be held in Boston, MA this year, October 7-10. Hear about Biosimilars, 340B, and more on Specialty Pharma and Managed Care issues. Don’t miss it.
|AMCP Nexus 2014 Looking For Moderators|
AMCP needs volunteers to moderate the educational sessions at AMCP Nexus 2014. As a moderator, you’ll make housekeeping announcements at the beginning and end of the session, introduce speakers, keep the session on track, facilitate the Q&A period and ensure that no product endorsements occur during the session. Applications must be received by August 22, 2014.
|Evidence Based Prescribing – Choosing Among Multiple Drugs|
Evidence-Based Prescribing: Combining Network Meta-Analysis With Multicriteria Decision Analysis to Choose Among Multiple Drugs is now available and requires a subscription to Circulation: Cardiovascular Quality and Outcomes. (Source: American Heart Association, 8/5/14).
|Will Medicare Premiums See An Increase In 2015?|
The Centers for Medicare & Medicaid Services (CMS) recently announced a minimal increase for 2015 Premiums for a basic Medicare Part D prescription drug plan, whereas Medicare Part B premiums are expected to stay the same. (Source: First Report Managed Care, 8/4/14).
|Save The Date: Specialty Data Optimization Summit|
This Summit takes place on December 11th in Philadelphia and will arm attendees with knowledge and actionable takeaways on how to unlock the power of specialty data to make informed, targeted decisions that take ROI to the next level. (Source: CBI).
|Selling Our Souls: The Commodification Of Hospital Care In The U.S.|
Selling Our Souls is an in-depth investigation into how hospital organizations and the people who work in them make sense of and respond to the modern health care market. The book features three hospitals in one California city and explains how these legacies play out today in terms of the hospitals’ different responses to similar market pressures, and the varieties of care that result. (Source: Adam Dalton Reich, amazon, 7/27/14).
|Job of the Week||Conference of the Week||Link of the Week|
Director Pricing and Market Access. ICON, location: US.
Who just added themselves to the only Business Directory for HEOR/Market Access? Context Matters, that’s who. Why aren’t you listed in HE Business Directory?
|Featured Jobs||Featured Webinars|